 Isoniazid preventive therapy HIV-infected intravenous drug abusers decision analysis Tuberculin skin testing poor marker tuberculosis infection patients positive human immunodeficiency virus decision analysis isoniazid tuberculosis patients decision intravenous drug abuser anergic tuberculin test status race gender assumptions parameter estimates investigation conservative vantage point use isoniazid preventive therapy Nevertheless results benefit use isoniazid preventive therapy groups tuberculin testing tuberculin-negative black women benefit isoniazid therapy patient life expectancy days Further decisions suspected incidence tuberculosis infection low Tuberculin important black women negative tuberculin skin tests candidates isoniazid therapy